MDC CONNECTS WEBINARS
UNDERSTANDING THE PK / PD RELATIONSHIP

  • Principles and modelling of pharmacokinetic and pharmacodynamic relationships - Graham Trevitt, XenoGesis
  • Understanding PK/PD using pre-clinical models: Lessons for efficacy studies - Jenny Worthington, AxisBio
  • Evaluation of clinical and pre-clinical pharmacodynamic endpoints using non-invasive imaging modalities - Neill Gingles, MDC

2pm BST, 27th May 2020

This webinar has already taken place

© Medicines Discovery Catapult 2020. All rights reserved. Read our Privacy Policy

Target Validation and Efficacy
2pm BST, Wednesday 3rd June 2020

  • Strategies for target and pathway engagement in cellular assays - Matt Burnham, MDC
  • Go native… Characterising therapeutic effect in primary cellular models - Amanda Woodrooffe, Precision Medicine
  • Use of pre-clinical models to deliver proof of concept efficacy - Lorraine Mooney, Alderley Oncology

Register for this webinar >



Is my Compound Safe?
2pm BST, Wednesday 10th June 2020

  • Making safety part of drug design - Richard Knight, Apconix
  • How to get your molecule into humans: A practical guide for the present and a look to the future - Malcolm Blackwell, Sequani
  • Challenges and opportunities of complex cell models in toxicity testing - Malcolm Haddrick, MDC

Register for this webinar >

Developing a Biomarker Strategy
2pm BST, Wednesday 17th June 2020

  • Designing a biomarker strategy - Gayle Marshall, MDC
  • The challenges of accessing clinical samples - Helen Hind, MDC
  • Biomarker identification: Assessing immune function - Russell Garland, Charles River Laboratories

Register for this webinar >

Other webinars in the series

About the presenters

Dr Graham Trevitt 

Graham is CSO and heads up the scientific team at XenoGesis. He joined XenoGesis in 2015, bringing over 14 years’ industrial drug discovery experience, as well as a track record of delivering pre-clinical drug candidates in oncology and inflammation through integration of DMPK properties into compound design to increase the probability of creating successful drugs. Prior to joining XenoGesis, Graham worked at UCB for 8 years before joining Almac Discovery in 2009. Graham graduated from the University of Nottingham with a PhD in Synthetic Organic Chemistry and went on to complete his Postdoctoral Research at the University of Geneva.